(Q37088895)

18 August 2017

1 reference

title

Mechanisms of disease: antiphospholipid antibodies-from clinical association to pathologic mechanism (English)

1 reference

18 August 2017

1 reference

Bas de Laat

1

1 reference

18 August 2017

Koen Mertens

series ordinal

2

1 reference

18 August 2017

Philip G de Groot

series ordinal

3

1 reference

18 August 2017

publication date

19 February 2008

1 reference

18 August 2017

number of pages

8

1 reference

Nature Clinical Practice Rheumatology

inferred from page(s)

published in

1 reference

18 August 2017

volume

4

1 reference

18 August 2017

issue

4

1 reference

18 August 2017

page(s)

192-199

1 reference

Biologically false positive serologic tests for syphilis; type, incidence, and cause

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0740

Use of single point mutations in domain I of beta 2-glycoprotein I to determine fine antigenic specificity of antiphospholipid autoantibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0740

The antiphospholipid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0740

7 January 2021

Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0740

7 January 2021

Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0740

7 January 2021

The natural history of systemic lupus erythematosus: An approach to its study through chronic biologic false positive reactors

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0740

7 January 2021

Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0740

7 January 2021

Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0740

7 January 2021

Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H)

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0740

7 January 2021

beta2-glycoprotein I, the playmaker of the antiphospholipid syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0740

7 January 2021

International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0740

7 January 2021

International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0740

7 January 2021

High prevalence of co-factor independent anticardiolipin antibodies in malaria exposed individuals

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0740

7 January 2021

Viral infections and antiphospholipid antibodies

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0740

7 January 2021

IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0740

7 January 2021

beta2-glycoprotein I-dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0740

7 January 2021

Antibody profiles for the diagnosis of antiphospholipid syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0740

7 January 2021

A functional coagulation test to identify anti-beta2-glycoprotein I dependent lupus anticoagulants.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0740

7 January 2021

A two-step coagulation test to identify antibeta-glycoprotein I lupus anticoagulants

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0740

7 January 2021

Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0740

7 January 2021

Detection of anti-recombinant beta 2-glycoprotein 1 and anti-recombinant beta 2-glycoprotein 1 fifth-domain antibodies in sera from patients with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0740

7 January 2021

Epitope studies with anti-beta 2-glycoprotein I antibodies from autoantibody and immunized sources

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0740

7 January 2021

Anti-beta2 glycoprotein I (beta2GPI) autoantibodies recognize an epitope on the first domain of beta2GPI.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0740

7 January 2021

Prevention of experimental antiphospholipid syndrome and endothelial cell activation by synthetic peptides

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0740

7 January 2021

Current concepts on the pathogenesis of the antiphospholipid syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0740

7 January 2021

Pregnancy loss in the antiphospholipid-antibody syndrome--a possible thrombogenic mechanism

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0740

7 January 2021

Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0740

7 January 2021

Correlation between antiphospholipid antibodies that recognize domain I of beta2-glycoprotein I and a reduction in the anticoagulant activity of annexin A5.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0740

7 January 2021

Detection of acquired resistance to activated protein C associated with antiphospholipid antibodies using a novel clotting assay

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0740

7 January 2021

Acquired activated protein C resistance associated with IgG antibodies against beta2-glycoprotein I and prothrombin as a strong risk factor for venous thromboembolism.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0740

7 January 2021

The binding site in {beta}2-glycoprotein I for ApoER2' on platelets is located in domain V.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0740

7 January 2021

Platelets express three different splice variants of ApoER2 that are all involved in signaling

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0740

7 January 2021

Current insight into diagnostics and pathophysiology of the antiphospolipid syndrome.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0740

7 January 2021

beta2-Glycoprotein I inhibits von Willebrand factor dependent platelet adhesion and aggregation

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0740

7 January 2021

The clearance of apoptotic cells: implications for autoimmunity

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0740

7 January 2021

Identifiers

DOI

10.1038/NCPRHEUM0740

1 reference

18 August 2017

1 reference